1-8 of 8
Atanasio Pandiella, MD,PhD
Close
Sort by
Journal Articles

Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Antonio Garcia-Gomez, Dalia Quwaider, Enrique M Ocio, MD, PhD, Laura San-Segundo, Teresa Paíno, Juan F Blanco, Allison J Berger, PhD, Atanasio Pandiella, MD, PhD, Jesús F San-Miguel, MD, PhD, Mercedes Garayoa
Journal: Blood
Blood (2012) 120 (21): 4014.
https://doi.org/10.1182/blood.V120.21.4014.4014
Published: 2012
Journal Articles

Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model.

Enrique M. Ocio, MD, PhD, David Vilanova, BS, Laura San-Segundo, BS, Patricia Maiso, BS, PhD, Mercedes Garayoa, BS, PhD, Peter Atadja, Atanasio Pandiella, MD, PhD, J.F. San Miguel, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 1514.
https://doi.org/10.1182/blood.V110.11.1514.1514
Published: 2007
Journal Articles

The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces In Vitro and In Vivo Antimyeloma Activity.

Enrique M. Ocio, MD, PhD, Patricia Maiso, BS, PhD, Mercedes Garayoa, BS, PhD, Marc Dupuis, Atanasio Pandiella, MD, PhD, J.F. San Miguel, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 1515.
https://doi.org/10.1182/blood.V110.11.1515.1515
Published: 2007
Journal Articles

The IGF1-R Inhibitor AEW541 Is a Potent Anti-Myeloma Agent That Overcomes Drugs Resistance, and Has Synergistic Activity with Other New Drugs.

Patricia Maiso, Enrique M. Ocio, MD,PhD, Mercedes Garayoa, PhD, Mark A. Pearson, MD,PhD, Atanasio Pandiella, MD,PhD, J.F. San Miguel, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 2599.
https://doi.org/10.1182/blood.V108.11.2599.2599
Published: 2006
Journal Articles

Proteasome Inhibitor Bortezomib Has Antitumour Activity Against Both CD34 Negative and CD34 Positive Acute Myeloid Leukemia Cells.

Enrique Colado, MD, Jesus Martin, MD, Maria-Belen Vidriales, MD,PhD, Atanasio Pandiella, MD,PhD, Dixie-Lee Esseltine, MD,FRCPC, Jose J. Perez, Enrique M. Ocio, MD,PhD, J.F. San Miguel, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 1989.
https://doi.org/10.1182/blood.V108.11.1989.1989
Published: 2006
Journal Articles

Role of c-Kit in Multiple Myeloma.

Juan Carlos Montero, PhD, J.F. San Miguel, Atanasio Pandiella, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 5047.
https://doi.org/10.1182/blood.V108.11.5047.5047
Published: 2006
Journal Articles

Bortezomib Induces Selective Depletion of Activated T Lymphocytes and Modifies the Cytokine’s Production Pattern.

Belen Blanco, PhD, Jose A. Perez-Simon, MD, PhD, Luis I. Sanchez-Abarca, PhD, Xonia Carvajal-Vergara, Juan Mateos, Belen Vidriales, MD, PhD, Natalia Lopez-Holgado, PhD, Mercedes Alberca, Eva Villaron, D. Schenkein, PhD, Consuelo Canizo, MD, PhD, Atanasio Pandiella, MD, PhD, Jesus F. San Miguel, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 615.
https://doi.org/10.1182/blood.V106.11.615.615
Published: 2005
Journal Articles

Comparisson of Molecular Mechanisms Altered by Treatment with Different Drugs ( Doxorubicin, Melphalan, Bortezomib, Aplidin and Arsenic Trioxide ) in Multiple Myeloma Patients Using Oligonucleotide Microarrays.

Patricia Maiso, BSC, Norma C. Gutierrez, MD, PhD, Ricardo Lopez-Perez, PhD, Gema Mateo, PhD, Isabel M. Isidro, BSC, Encarna Ferminan, PhD, Xonia Carvajal-Vergara, BSC, Juan C. Montero, PhD, Jesus M. Hernandez, MD, PhD, Atanasio Pandiella, MD, PhD, Jesus F. San Miguel, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 2457.
https://doi.org/10.1182/blood.V104.11.2457.2457
Published: 2004